INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 135 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2018. The put-call ratio across all filers is 0.27 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $649,000 | -39.6% | 18,921 | -86.9% | 0.03% | -40.7% |
| Q3 2019 | $1,075,000 | +149.4% | 143,921 | +333.2% | 0.05% | +125.0% |
| Q2 2019 | $431,000 | +31.8% | 33,221 | +23.9% | 0.02% | +20.0% |
| Q1 2019 | $327,000 | -33.3% | 26,818 | -37.6% | 0.02% | -37.5% |
| Q4 2018 | $490,000 | -42.2% | 42,996 | +10.0% | 0.03% | -17.9% |
| Q3 2018 | $848,000 | -19.7% | 39,096 | -34.6% | 0.04% | -9.3% |
| Q2 2018 | $1,056,000 | -10.0% | 59,796 | -26.2% | 0.04% | -17.3% |
| Q4 2017 | $1,173,000 | -47.3% | 81,010 | -42.6% | 0.05% | -54.4% |
| Q3 2017 | $2,227,000 | +246.9% | 141,157 | +173.1% | 0.11% | +235.3% |
| Q2 2017 | $642,000 | -60.9% | 51,693 | -48.9% | 0.03% | -55.3% |
| Q1 2017 | $1,644,000 | +9.7% | 101,200 | +1.9% | 0.08% | -14.6% |
| Q4 2016 | $1,498,000 | – | 99,300 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |